[go: up one dir, main page]

WO2008130668A3 - Mo-1, gene associe a l'obesite morbide - Google Patents

Mo-1, gene associe a l'obesite morbide Download PDF

Info

Publication number
WO2008130668A3
WO2008130668A3 PCT/US2008/005083 US2008005083W WO2008130668A3 WO 2008130668 A3 WO2008130668 A3 WO 2008130668A3 US 2008005083 W US2008005083 W US 2008005083W WO 2008130668 A3 WO2008130668 A3 WO 2008130668A3
Authority
WO
WIPO (PCT)
Prior art keywords
morbid obesity
screening
disclosed
gene associated
nucleic acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/005083
Other languages
English (en)
Other versions
WO2008130668A2 (fr
Inventor
Adel Shalata
John Martignetti
Robert Desnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Priority to US12/596,776 priority Critical patent/US20100077496A1/en
Priority to CA002684707A priority patent/CA2684707A1/fr
Publication of WO2008130668A2 publication Critical patent/WO2008130668A2/fr
Publication of WO2008130668A3 publication Critical patent/WO2008130668A3/fr
Anticipated expiration legal-status Critical
Priority to US13/650,968 priority patent/US20130254908A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne MO-I, un gène récemment identifié et un produit génique associés à l'obésité morbide. Dans certains aspects, l'invention concerne des acides nucléiques de MO-I isolés, des polypeptides de MO-I, des oligonucléotides s'hybridant avec des acides nucléiques de MO-I, ainsi que des vecteurs, notamment des vecteurs d'expression, contenant des acides nucléiques de MO-I. L'invention concerne également des cellules hôtes isolées, des anticorps, des animaux non humains transgéniques, des compositions et des kits associés à MO-I. Dans d'autres aspects, l'invention concerne encore des procédés de détection de la présence d'acides nucléiques de MO-I, des procédés de criblage d'agents modifiant l'activité de MO-I et des procédés de criblage de variants de MO-I.
PCT/US2008/005083 2007-04-20 2008-04-21 Mo-1, gene associe a l'obesite morbide Ceased WO2008130668A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/596,776 US20100077496A1 (en) 2007-04-20 2008-04-21 MO-1, A Gene Associated With Morbid Obesity
CA002684707A CA2684707A1 (fr) 2007-04-20 2008-04-21 Mo-1, gene associe a l'obesite morbide
US13/650,968 US20130254908A1 (en) 2007-04-20 2012-10-12 MO-1, A Gene Associated With Morbid Obesity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92540107P 2007-04-20 2007-04-20
US60/925,401 2007-04-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/650,968 Continuation US20130254908A1 (en) 2007-04-20 2012-10-12 MO-1, A Gene Associated With Morbid Obesity

Publications (2)

Publication Number Publication Date
WO2008130668A2 WO2008130668A2 (fr) 2008-10-30
WO2008130668A3 true WO2008130668A3 (fr) 2009-01-15

Family

ID=39876129

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/005083 Ceased WO2008130668A2 (fr) 2007-04-20 2008-04-21 Mo-1, gene associe a l'obesite morbide

Country Status (3)

Country Link
US (2) US20100077496A1 (fr)
CA (1) CA2684707A1 (fr)
WO (1) WO2008130668A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL201999A (en) 2009-11-08 2017-10-31 Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel A knockout mouse of the 1 – mo gene, a gene associated with morbidly extreme obesity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002078420A2 (fr) * 2001-03-30 2002-10-10 Incyte Genomics, Inc. Molecules pour la detection et le traitement de maladies
US20040101884A1 (en) * 2002-03-29 2004-05-27 Lu Dyung Aina M Molecules for disease detection and treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US5272065A (en) * 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4736866A (en) * 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002078420A2 (fr) * 2001-03-30 2002-10-10 Incyte Genomics, Inc. Molecules pour la detection et le traitement de maladies
US20040101884A1 (en) * 2002-03-29 2004-05-27 Lu Dyung Aina M Molecules for disease detection and treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MAMMALIAN GENE COLLECTION (MGC) PROGRAM TEAM: "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA squences", PNAS, vol. 99, no. 26, December 2002 (2002-12-01), pages 16899 - 16903, XP002964739, DOI: doi:10.1073/pnas.242603899 *

Also Published As

Publication number Publication date
US20100077496A1 (en) 2010-03-25
US20130254908A1 (en) 2013-09-26
CA2684707A1 (fr) 2008-10-30
WO2008130668A2 (fr) 2008-10-30

Similar Documents

Publication Publication Date Title
WO2010028347A3 (fr) Evolution dirigée continue de protéines et d'acides nucléiques
BRPI0719672A2 (pt) Molécula isolada de ácido nucleico, vetor, célula hospedeira, planta transgênica, semente transgênica, polipeptídeo isolado, método para produzir um polipeptídeo com atividade de resistência a herbicidas, método para conferir resistência a um herbicida em uma planta, planta, método para aumentar o vigor ou rendimento de uma planta, método para conferir resistência ao glifosato a uma planta
WO2007134272A3 (fr) Génération de modèles animaux
EP2484763A3 (fr) Neukinase, protéine en aval de la neuréguline
BRPI0909611A2 (pt) ''polinucleotídeo isolado, construção de dna recombinante, célula, oleaginosa transgênica, método de aumento do teor total de ácido graxo de oleginosas, método de aumento do teor total de ácido graxo de uma célula de oleaginosa, fragmento de ácido nucleico, fragmento de ácido nucleico isolado e célula fúngica''
WO2009073345A3 (fr) Dosage pour détecter des anomalies génétiques dans des acides nucléiques génomiques
WO2006031745A3 (fr) Methodes d'analyse de sequence d'acide nucleique superieure
WO2009077478A3 (fr) Promoteurs dérivés de brassica napus pour l'expression génétique spécifique de graines
BRPI0822090A2 (pt) polipeptídeo isolado, polinucleotídeo isolado, construção de ácido nucléico, célula hospedeira recombinante, métodos para produzir o polipeptídeo, para produzir um mutante de uma célula precursora, de inibir a expressão de um polipeptídeo, para produzir uma proteína, para degradar ou converter um material celulósico, para a produção de um produto de fermentação, para fermentar um material celulósico, planta transgênica, parte vegetal ou célula vegetal, molécula de rna inibidora de duplo filamento
WO2006094976A3 (fr) Sequences introniques facilitant l'expression
WO2010000708A3 (fr) Promoteurs de brassica napus pour l'expression de gènes spécifique de graines
WO2012051199A3 (fr) Plante et semence de soja correspondant à l'événement transgénique mon87712 et procédé pour les détecter
WO2008006028A3 (fr) Recombinases chimères à doigts de zinc optimisées pour catalyse par évolution directe
WO2007095496A8 (fr) Selection et stabilisation de constructions d'arn double brin
WO2008058282A3 (fr) Procédés et compositions pour analyse à grande échelle d'acides nucléiques par suppressions d'adn
WO2010048337A3 (fr) Préservation d'informations liées à une méthylation d'adn génomique
BRPI0820613A2 (pt) Polipeptídeo isolado, construção de ácido nucléico, célula hospedeira recombinante, métodos de produzir o polipeptídeo, de produzir um mutante de uma célula precursora, de inibir a expressão de um polipeptídeo tendo atividade de endoglicanase em uma célula, de degradar ou converter um material celulósico, de produzir um produto de fermentação e de produzir uma proteína, planta transgênica, parte de planta ou célula vegetal, molécula de rna inibidora de filamento duplo, construção de ácido nucléico, e, célula hospedeira recombinante
WO2010117817A3 (fr) Méthodes de génération de sondes spécifiques cibles pour capture en solution
BRPI0821048A2 (pt) Polipeptídeo e polinucleotídeo isolados, construção de ácido nucléico, célula hospedeira recombinante, métodos para produzir o polipeptídeo, um mutante de uma célula precursora, uma proteína e um produto de fermentação, para inibir a expressão de um polipeptídeo, para degradar ou converter um material celulósico, e para fermentar um material celulósico, planta trangênica, parte vegetal ou célula vegetal, e, melécula de rna inibidora
WO2008154695A8 (fr) Procédé permettant d'améliorer la résistance à un stress de plantes et de leurs matériaux
BRPI0906241A2 (pt) Molécula de ácido nucléico isolada, gene quimérico, vetor e método de transformação de uma célula bacteriana.
WO2008098216A3 (fr) Compositions et procédés destinés à prévenir le cancer avec des cupredoxines
EP2257566A4 (fr) Gènes et enzymes transporteurs de glucides thermophiles et thermoacidophiles d alicyclobacillus acidocaldarius et organismes et procédés associés
BRPI0908892A2 (pt) enzimas e genes de glicosilação termoacidofílica e termofílica de alicyclobacillus acidocaldarius e métodos e organismos relacionados
EP2474619A4 (fr) Méthode spécifique pour la préparation de fragments d'adn assemblés comprenant des séquences dérivées de gènes cibles

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08743110

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2684707

Country of ref document: CA

Ref document number: 12596776

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08743110

Country of ref document: EP

Kind code of ref document: A2